While our findings provide compelling mechanistic insights and preliminary evidence of therapeutic potential, further validation in diverse and clinically relevant in vivo models is essential to fully assess the translational relevance of WNK1 targeting in AML. This evidence concerns the gene WNK1 and acute myeloid leukemia.